Novartis associates participate in first company-wide health and well-being initiative
- Details
- Category: Novartis
Novartis Group Company associates across 32 countries will participate in a new Novartis health and well-being initiative during the first Novartis Be Healthy Celebration Week from September 19-23, 2011.
Prolia® (Denosumab) Phase 2 Extension Study
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN) announced new long-term data showing that Prolia® (denosumab) treatment for up to eight years in postmenopausal women with low bone mass or osteoporosis was associated with a continued increase in bone mineral density (BMD), an important determinant of bone strength, and a persistent reduction in markers of bone turnover.
Merck Statement on GARDASIL®
- Details
- Category: Merck
Merck (NYSE:MRK), known as MSD outside the United States and Canada, issued the following statement on GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant], Merck's vaccine to protect against certain diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18.
Lilly Invests $30 Million in Partnership to Address Non-Communicable Diseases
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company announced a $30 million commitment over five years to fight the rising burden of non-communicable diseases in developing nations.
Boehringer Ingelheim and EFSD collaborate to support diabetes research in Europe
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and the European Foundation for the Study of Diabetes (EFSD) today announced a new partnership to establish a €2.5 million research grant programme, encouraging diabetes research over the next three years.
Novartis increases growth potential through integration of Alcon
- Details
- Category: Novartis
Novartis presented an update on its long-term strategy, performance and vision for continued sustainable growth and gave an in-depth overview on the unique position and business model of the new Alcon Division.
Initiation of Lantus leads to better glycemic control at similar weight gain
- Details
- Category: Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) announced data that demonstrates that initiating Lantus® (insulin glargine [rDNA origin] injection) in type 2 diabetes patients leads to better glycemic control and comparable and modest weight gain versus a comparator group consisting of other insulins, oral antidiabetics (OADs) and dietary changes.
More Pharma News ...
- Roche named Dow Jones Sustainability Index leader in healthcare for third consecutive year
- Bristol-Myers Squibb Completes Acquisition of Amira Pharmaceuticals
- GSK awarded contract by BARDA to support research on potential novel antibiotic
- Bayer Confident in Results of ROCKET AF Study
- Roche’s Tarceva receives European approval for first-line use in a genetically distinct type of lung cancer
- Novartis drug Afinitor® gains EU approval to treat patients with advanced pancreatic neuroendocrine tumors
- AstraZeneca announces top-line results from SATURN study